title: Progress against solid tumors in danger: the metastatic breast cancer example.
authors.affiliation: Department of Oncology, Vall d'Hebron University Hospital, P° Vall d'Hebron 129-139, 08035 Barcelona, Spain; jacortes@vhio.net
authors.forename: Javier
authors.initials: J
authors.lastname: Cortés
authors.forename: Emiliano
authors.initials: E
authors.lastname: Calvo
authors.forename: Antonio
authors.initials: A
authors.lastname: González-Martín
authors.forename: Shaheenah
authors.initials: S
authors.lastname: Dawood
authors.forename: Antonio
authors.initials: A
authors.lastname: Llombart-Cussac
authors.forename: Leticia
authors.initials: L
authors.lastname: De Mattos-Arruda
authors.forename: Patricia
authors.initials: P
authors.lastname: Gómez
authors.forename: Orlando
authors.initials: O
authors.lastname: Silva
authors.forename: Edith A
authors.initials: EA
authors.lastname: Perez
authors.forename: Hope S
authors.initials: HS
authors.lastname: Rugo
authors.forename: Ana
authors.initials: A
authors.lastname: Lluch
authors.forename: Gabriel N
authors.initials: GN
authors.lastname: Hortobagyi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D018572:Disease-Free Survival; D017277:Drug Approval; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab